Friday, October 20, 2017 9:55:58 AM
But I don’t think I am wrong in pointing out the inequities of the “sales-purchase” contract between Medinah and Auryn. I just hope that the confidence that shareholders have in Auryn’s commitment to execute their business plan will reward shareholders with an appreciation of our share price. In time we will know how this will turn out.
Surwin made a post which probably was directed at me,
“I look at it this way if one does not trust Auryn then one should not be invested in MDMN”.
Do I have a choice to “trust” Auryn or get out of this investment. Sure, I have a choice, every shareholder knows that. But it’s not a matter of trust for me. I simply refuse at this time to sell and take the loss that would come with that decision.
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM